Global Neurology Academy

A New Hope for Patients with MS – The First FDA-Approved Biosimilar  

A New Hope for Patients with MS – The First FDA-Approved Biosimilar
RestartResume

    A major milestone in the management of MS has been achieved with the recent FDA approval of its biosimilar.

    • Overview

      This new disease-modifying treatment provides a more affordable option for patients with relapsing forms of MS, thus increasing the accessibility for patients with relapsing forms of MS and Crohn’s disease. Read more about the safety and efficacy of natalizumab-sztn from the recent clinical trial.

    Facebook Comments

    Register

    We’re glad to see you’re enjoying Global Neurology Academy…
    but how about a more personalized experience?

    Register for free